drugset / Trial / NCT06339710

Short Benznidazole Regimen for Chronic Phase Chagas Disease Patients

NCT06339710

RandomizedParallel-groupTriple-blindTreatment

Summary

Multicentric study on Chagas disease that seeks to evaluate a new treatment regimen using the drug benznidazole. Currently, existing treatment regimens are long and have frequent side effects, which leads to a high dropout rate among patients. The research proposes testing two shorter benznidazole regimens to see if they are as effective as standard treatment, but with fewer side effects. The study will have 672 participants and will be carried out in four locations, Bolivia and Colombia. The objective is to analyze the efficacy and safety of new treatment regimens, evaluating the parasitological response in comparison with standard treatment. In addition, an economic assessment will be carried out to analyze direct and indirect costs, including procedures associated with the management of adverse events.

Timeline

Start
2025-01-30
Primary completion
2026-01-30
Completion
2026-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Benznidazole Small molecule 300 mg

Indications